US › Healthcare

Pmv Pharmaceuticals Inc (PMVP)

US · Healthcare · Biotechnology

$1.46+2.10%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-18.1M

EPS

$-0.34

EPS estimate

$-0.38

EPS came in at -0.34 against a street estimate of -0.38 — a beat of 10.5%.

Key statistics

Market cap

$74.8M

Forward P/E

0.0

P/B

1.06

Book value

$1.34

EPS (TTM)

$-1.42

52-week high

$1.88

52-week low

$1.02

50-day MA

$1.26

200-day MA

$1.27

Beta

1.37

Analyst view

Analysts rate Pmv Pharmaceuticals Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $4.20.

Shareholding

Insiders

2.37%

Institutions

45.67%

Largest institutional holders

Fund	Stake
BML Capital Management LLC	9.99%
TANG CAPITAL MANAGEMENT LLC	7.96%
Sio Capital Management, LLC	4.94%
Euclidean Capital LLC	4.93%
Adage Capital Partners Gp LLC	4.43%
Acadian Asset Management LLC	4.15%
Vanguard Capital Management, LLC	3.70%
ArrowMark Colorado Holdings, LLC (ArrowMark Partners)	3.67%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pmv Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.